Abstract
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer accounting for about 85% of all lung cancer cases. Its 5-year survival rate remains at approximately 17%. Almost half of cases have locally advanced or widespread metastasis at diagnosis. In addition, it is therapeutically limited. Despite the successful use of small molecule inhibitors, a major problem reminiscent …